Company Registration No. 4651691

SUNRISE MEDICAL HOLDINGS LIMITED

Report and Financial Statements

30 June 2013



12/03/2014 COMPANIES HOUSE

CONTENTS

	Page
Officers and professional advisers	1
Directors' report	2
Directors' responsibilities	3
Independent auditors' report	4
Profit and loss account	5
Balance sheet	6
Notes to the financial statements	7

OFFICERS AND PROFESSIONAL ADVISERS

DIRECTORS

P Riley E O'Brien T J Rossnagel R F Smith

SECRETARY

P Riley

REGISTERED OFFICE

Thoms Road Brierley Hill West Midlands DY5 2LD

AUDITORS

Deloitte LLP Statutory Auditors Birmingham, United Kingdom

DIRECTORS' REPORT

The directors present their annual report and the audited financial statements for the year ended 30 June 2013

PRINCIPAL ACTIVITIES AND BUSINESS REVIEW

The principal activity of the company is acting as an investment and management services company. Future developments are likely to be in similar fields

The director's report has been prepared in accordance with the provisions applicable to companies entitled to the small company s exemption

The results for the year are as follows	2013	2012
	£'000	£'000
Profit/(Loss) on ordinary activities after taxation	(273)	(487)

LIQUIDITY

The company's activities are described above. The directors believe the company is structured to successfully manage and control the business risks it faces as an integral part of the broader Sunnse Medical group, despite the current economic uncertainty. Should it be required, the company will receive the support of fellow group companies in managing future cash flows, although such support is not confirmed as being legally binding. On this basis the directors have a reasonable expectation that the company can continue in operational existence for the foreseeable future and they can therefore continue to adopt the going concern basis in preparing the annual report and accounts.

DIVIDEND

During the year, the directors recommended the payment of a dividend of £nil (2012 £7,745,313)

AUDITORS

Each of the persons who is a director at the date of approval of this report confirms that

- (1) so far as the director is aware, there is no relevant audit information of which the company's auditors are unaware, and
- (2) the director has taken all the steps that he/she ought to have taken as a director in order to make himself/herself aware of any relevant audit information and to establish that the company's auditors are aware of that information

This confirmation is given and should be interpreted in accordance with the provision of \$418 of the Companies Act 2006

REAPPOINTMENT OF AUDITORS

Deloitte LLP has expressed their willingness to continue in office as auditors and a resolution to re-appoint them will be proposed at the forthcoming Annual General Meeting

Approved by the Board of Directors and signed on behalf of the Board

P Kiley Secretary

Date 29 November 2013

DIRECTORS' RESPONSIBILITIES STATEMENT

The directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulations

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to

- · select suitable accounting policies and then apply them consistently,
- · make judgments and accounting estimates that are reasonable and prudent, and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF SUNRISE MEDICAL HOLDINGS LIMITED

We have audited the financial statements of Sunrise Medical Holdings Limited for the year ended 30 June 2013 which comprises the Profit and Loss Account, the Balance Sheet, and the related notes 1 to 18. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice)

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed

Respective responsibilities of directors and auditors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's (APB's) Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed, the reasonableness of significant accounting estimates made by the directors, and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the annual report to identify material inconsistencies with the audited financial statements. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements

- give a true and fair view of the state of the company's affairs as at 29 June 2012 and of its loss for the year then ended,
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice,
- have been prepared in accordance with the requirements of the Companies Act 2006

Opinion on other matter prescribed by the Companies Act 2006

In our opinion the information given in the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us, or
- the financial statements are not in agreement with the accounting records and returns, or
- certain disclosures of directors' remuneration specified by law are not made, or
- we have not received all the information and explanations we require for our audit, or
- the directors were not entitled to take advantage of the small companies exemption in preparing the directors' report

Peter Gallimore FCA (Senior Statutory Auditor)

for and on behalf of Deloitte LLP

Chartered Accountants and Statutory Auditors

Birmingham, United Kingdom

21 Niverno 1, 3613

PROFIT AND LOSS ACCOUNT Year ended 30 June 2013

	Note	2013 £ 000	2012 £ 000
Administrative costs	5	(22)	
OPERATING LOSS	4	(22)	-
Interest receivable and similar income Interest payable and similar charges	6 6	376 (693)	472 (1,114)
(LOSS) ON ORDINARY ACTIVITIES BEFORE TAXATION		(339)	(642)
Tax on (loss) on ordinary activities	7	66	155
(LOSS) ON ORDINARY ACTIVITIES AFTER TAXATION	14	(273)	(487)

All results derive from continuing operations. There are no recognised gains and losses other than the result for the financial years. Accordingly, no statement of total recognised gains and losses is given

BALANCE SHEET 30 June 2013

	Note	£ 000	2013 £ 000	£ 000	2012 £ 000
FIXED ASSETS Investments	8		26, 762		21,508
CURRENT ASSETS Debtors	9	8,947		8,418	
CREDITORS: amounts falling due within one year	11	(309)		(198)	
NET CURRENT ASSETS			8,638		8,220
TOTAL ASSETS LESS CURRENT LIABILITIES			35,400	•	29,728
CREDITORS: amounts falling due after more than one year	12		(4,792)		(20,793)
NET ASSETS			30,608	-	8,935
CAPITAL AND RESERVES					
Called up share capital	13		30,231		8,285
Profit and loss account	14		377		650
EQUITY SHAREHOLDERS' FUNDS	15		30,608		8,935

The financial statements of Sunrise Medical Holdings Limited (Registration Number 4651691) were approved by the board of directors and authorised for issue on 29 November 2013. They were signed by

P Riley

Director

NOTES TO THE FINANCIAL STATEMENTS Year ended 30 June 2013

1. ACCOUNTING POLICIES

The financial statements have been prepared in accordance with applicable United Kingdom accounting standards and have been applied consistently throughout the year and the preceding year. The particular accounting policies adopted by the directors are described below

Accounting convention

The financial statements are prepared under the historical cost convention

At the balance sheet date, the company was a wholly owned subsidiary of Sunnse Medical Inc and is included in that company's consolidated financial statements

The company has taken advantage of the exemption from preparing consolidated financial statements afforded by the Urgent Issues Task Force (UITF) abstract No 43 "The interpretation of equivalence for the purposes of section 401 of the Companies Act 2006' because it is a wholly owned subsidiary of Sunrise Medical Inc which prepared publicly available consolidated financial statements that incorporate the results of the company and are drawn up in accordance with the Seventh Directive

Cash flow statement

The Company has taken advantage of the exemption granted by Financial Reporting Standard 1 - 'Cash Flow Statements' and does not therefore provide a cash flow statement as it was a wholly owned subsidiary of Sunrise Medical LLC at the balance sheet date, the accounts of which are publicly available

Liquidity and going concern

The company's activities are described in the directors' report. The directors believe the company is structured to successfully manage and control the business risks it faces as an integral part of the broader Sunrise Medical group, despite the current economic uncertainty. Should it be required, the company will receive the support of fellow group companies in managing future cash flows, although such support is not confirmed as being legally binding. On this basis the directors have a reasonable expectation that the company can continue in operational existence for the foreseeable future and they can therefore continue to adopt the going concern basis in preparing the annual report and accounts.

Investments

Fixed asset investments are recorded at cost less provision for impairment

Taxation

UK corporation tax is provided at amounts expected to be paid (or recovered) using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date

Deferred taxation is provided in full on timing differences which result in an obligation at the balance sheet date to pay more tax, or a right to pay less tax, at a future date, at rates expected to apply when they crystallise based on current tax rates and law. Timing differences arise from the inclusion of items of income and expenditure in taxation computations in periods different from those in which they are included in financial statements.

Deferred tax is not provided on timing differences from the revaluation of fixed assets where there is no commitment to sell the asset, or on unremitted earnings where there is no commitment to remit these earnings Deferred tax assets are recognised to the extent that it is regarded as more likely than not that they will be recovered. Deferred tax assets and liabilities are not discounted

Foreign exchange

Transactions denominated in foreign currencies are translated into sterling at the rates ruling at the dates of the transactions, or where there are forward currency contracts, at the contracted rate. Monetary assets and liabilities denominated in foreign currencies at the balance sheet date are translated at the rates ruling at that date, or the forward currency contracted rate, whichever is applicable. These translation differences are dealt with in the profit and loss account.

NOTES TO THE FINANCIAL STATEMENTS (continued) Year ended 30 June 2013

2. DIRECTORS' EMOLUMENTS

Mr T Rossnagel and Mr R Smith are overseas directors and it is not practicable to apportion their remuneration between the companies of which they are directors

Mr E O'Brien and Mr P Riley were employees of Sunrise Medical Ltd and their remuneration costs were borne by that company It is not practicable to apportion their remuneration between the companies

3. INFORMATION REGARDING EMPLOYEES

No staff have been employed in the year by the company (2012 Nil)

4. OPERATING LOSS

The operating loss of £21,784 (2012 £486) includes audit fees of £5,000 (2012 £5,000)

5 ADMINISTRATIVE COSTS

	2013 £ 000	2012 £ 000
Professional fees Impairment of investment	21 1	-
	22	-
INTEREST		
	2013 £ 000	2012 £ 000
Interest payable and similar charges	2 000	2000
Interest on loans from group undertakings	693	1,114
	693	1,114
Interest receivable and similar income		
Interest on loans to group undertakings	376	472
	376	472
	Interest payable and similar charges Interest on loans from group undertakings Interest receivable and similar income	Professional fees Impairment of investment Interest payable and similar charges Interest on loans from group undertakings Interest receivable and similar income Interest on loans to group undertakings 376

NOTES TO THE FINANCIAL STATEMENTS (continued) Year ended 30 June 2013

7 TAX ON PROFIT/(LOSS) ON ORDINARY ACTIVITIES

	2013 £ 000	2012 £000
Current tax		
United Kingdom corporation tax at 23 25% (2012	-	-
25 5%)		
Group Relief		/ a = as
Current year	(66)	(155)
Prior year adjustment		*
Total current tax	(66)	(155)
Deferred taxation		
Current year	<u> </u>	-
Tax (credit) on profit/(loss) on ordinary activities	(66)	(155)

Factors affecting tax credit in year

The standard rate of tax for the year, based on the UK standard rate of corporation tax, is 23 25% (2012 25 5%). The actual tax charge for the current and the previous periods differs from the standard rate for the reasons set out in the following reconciliation.

	2013 £ 000	2012 £ 000
(Loss) on ordinary activities before taxation	(338)	(642)
Tax on (loss) on ordinary activities at standard rate	(79)	(164)
Effects of Disallowed expenses and non-taxable income	5	(1)
Group relief surrendered for no payment	8	10
Prior year adjustment	<u> </u>	-
Current tax (credit)	(66)	(155)

Finance Act 2013 lowered the rate of UK Corporation from 24% to 21%, effective on 1 April 2013 UK GAAP requires that only those laws enacted or substatively enacted by the balance sheet date taken into account in deciding on the appropriate tax rate. Ordinarily, as Finance Act 2013 did not complete its passage through the House of Commons until 17 July 2013, it would not normally be considered to be substantively enacted until that point However, as the House of Commons passed a Budget resolution which falls within the provisions of the Provisional Collection of Taxes Act 1968 in March 2013 regarding the 21% rate, it is considered to have statutory effect from that date

Therefore these accounts only reflect the full change in rate from 24% to 21%. Current tax is therefore provided at a blended rate of 23 25% and deferred tax at 21%. For future periods a rate will be utilised of 21% for both current and deferred tax, subject to any further legislative changes enacted by the UK Parliament

NOTES TO THE FINANCIAL STATEMENTS (continued) Year ended 30 June 2013

8. FIXED ASSET INVESTMENTS

The company had the following investments at 30 June 2013

Name of subsidiary undertaking	Class of shares held	Proportion held	Nature of business
Sunrise Medical Limited *	Ordinary	100%	Manufacture and sale of healthcare products
Lomax Mobility Limited	Ordinary	100%	Dormant
Sunrise Medical Poland Sp Zoo *	Ordinary	100%	Sale of healthcare products
Sunrise Medical (China) No 1 Limited *	Ordinary	100%	Holding company
Medicco srl *	Ordinary	15%	Sale of healthcare products
Sunrise Medical Equipment (Shanghai) Co Ltd	Ordinary	100%	Sale of healthcare products
Xıamen Lomax Industrial Co Ltd	Ordinary	80%	Manufacture of healthcare products

^{*} Direct subsidiary of Sunrise Medical Holdings Limited

Sunrise Medical Limited, Sunrise Medical (China) No 1 Limited are incorporated in Great Britain and registered in England and Wales
Lomax Mobility Limited is incorporated and registered in Scotland Xiamen Lomax Industrial Co Ltd and Sunrise Medical Equipment (Shanghai) Limited are incorporated and registered in China Sunrise Medical Poland Sp Zoo is incorporated and registered in Poland Medicco srl is incorporated and registered in the Czech Republic

Summary information on investments in subsidiary undertakings is as follows

	Shares in subsiduary undertakings £ 000
Cost	
At 30 June 2012	35,357
Investment in the year	5,255
At 30 June 2013	40,612
Provisions	
At 30 June 2012	13,849
Impairment of Medicco srl	<u> </u>
At 30 June 2013	13,850
Net Book Value	
At 30 June 2012	21,508
At 30 June 2013	26,762

NOTES TO THE FINANCIAL STATEMENTS (continued) Year ended 30 June 2013

9. DEBTORS

12

	2013 £ 000	2012 £ 000
Amounts owed by group undertakings & fellow group subsidiaries	8,947	8,418
	8,947	8,418

10 DEFERRED TAXATION

A deferred tax asset of £149,000 (2012 £170,000) in respect of losses carried forward has not been recognised, as there is no certainty that the asset will reverse in the foreseeable future

11. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2013	2012
	£ 000	£ 000
Amount owed to group undertakings & fellow group		
subsidiaries	304	193
Accruals	5	5
_	309	198
Amounts owed to group undertakings are denominated in Sterling		
CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR	2	
	2013	2012
	£ 000	£ 000
Amount owed to group undertakings	4,792	20,793

Amounts owed to group undertakings relate to a single loan denominated in Sterling at £4,634,942 and accrued interest of £157,166. The interest rate is 6 48% and the loan is repayable on 30 June 2017, therefore the full amount is due to be paid within five years

4,792

20,793

NOTES TO THE FINANCIAL STATEMENTS (continued) Year ended 30 June 2013

13. CALLED UP SHARE CAPITAL

		2013 £ 000	2012 £ 000
	Authorised		
	50,000,000 Ordinary shares of £1 each	50,000	50,000
	Called up, allotted and fully paid		
	30,231,184 Ordinary shares of £1 each (2012 8,285,000)	30,231	8,285
14.	PROFIT AND LOSS ACCOUNT		
			£ 000
	Retained profit brought forward		650
	Loss for the financial year	_	(273)
	Retained surplus carried forward	=	377
15.	RECONCILIATION OF MOVEMENTS IN SHAREHOLDERS' FUNDS		
		2013 £ 000	2012 £ 000
	(Loss) for the financial year	(273)	(487)
	Dividend paid	-	(7,745)
	Issuance of new capital	21,946	
	Net addition/(reduction in) to shareholders' funds	21,673	(8,232)
	Opening shareholders funds	8,935	17,167
	Closing shareholders' funds	30,608	8,935

16. RELATED PARTY TRANSACTIONS

Advantage has been taken of the exemption available under FRS 8 to dispense with the requirement to disclose transactions with fellow wholly-owned members of a group which produces consolidated financial statements that are publicly available. There were no transactions with Xiamen Lomax Industrial Co Ltd (an 80% holding)

17. ULTIMATE PARENT COMPANY

At the balance sheet date, the company's ultimate parent company and controlling party was Apollo Bidco S à rl, a company incorporated in Luxembourg. The company's immediate parent company is Sunrise Medical (Luxembourg) Investments Sarl, a company incorporated in Luxembourg. The parent company of the smallest group to consolidate financial statement was Apollo Bidco S a rl. Copies of these financial statements may be obtained from Sunrise Medical Limited, Thorns Road, Brierley Hill, West Midlands DY5 2LD

18 CONTINGENT LIABILITIES

The company together with certain other United Kingdom companies has entered into cross guarantees with Commerzbank and Deutsche Bank in respect of the borrowings of the group companies concerned at the year end